PE20121636A1 - Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas - Google Patents

Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas

Info

Publication number
PE20121636A1
PE20121636A1 PE2012000720A PE2012000720A PE20121636A1 PE 20121636 A1 PE20121636 A1 PE 20121636A1 PE 2012000720 A PE2012000720 A PE 2012000720A PE 2012000720 A PE2012000720 A PE 2012000720A PE 20121636 A1 PE20121636 A1 PE 20121636A1
Authority
PE
Peru
Prior art keywords
cancer
cells
therapeutic use
chronic infections
refers
Prior art date
Application number
PE2012000720A
Other languages
English (en)
Inventor
Monzon Kalet Leon
Portilla Tania Carmenate
Martinez Karina Garcia
Davila Agustin Bienvenido Lage
Rodriguez Saumel Perez
Roche Diamile Gonzales
Perera Gabriel Marquez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43646474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121636(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of PE20121636A1 publication Critical patent/PE20121636A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UN POLIPEPTIDO INMUNOMODULADOR DERIVADO DE LA IL-2 QUE COMPRENDE VARIAS MUTACIONES DENTRO DE LA SECUENCIA DE LA IL-2 NATIVA TALES COMO Q22V, Q126A, I129D, S130G, ENTRE OTROS, LAS CUALES LE CONFIEREN LA PROPIEDAD DE INHIBIR LA ACTIVIDAD DE IL-2 SOBRE CELULAS T REGULADORAS IN VITRO, CELULAS T REGULADORAS NATURALES Y CELULAS T REGULADORAS IN VIVO. TAMBIEN SE REFIERE A UNA PROTEINA DE FUSION QUE COMPRENDE EL POLIPEPTIDO INMUNOMODULADOR ACOPLADO A UNA PROTEINA TRANSPORTADORA TAL COMO ALBUMINA O LA REGION Fc DE LA INMUNOGLOBULINA HUMANA, Y A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE CANCER Y ENFERMEDADES INFECCIOSAS CRONICAS
PE2012000720A 2009-11-27 2010-11-26 Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas PE20121636A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20090203A CU23734A1 (es) 2009-11-27 2009-11-27 Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas

Publications (1)

Publication Number Publication Date
PE20121636A1 true PE20121636A1 (es) 2012-12-03

Family

ID=43646474

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000720A PE20121636A1 (es) 2009-11-27 2010-11-26 Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas

Country Status (24)

Country Link
US (1) US8759486B2 (es)
EP (1) EP2505206B1 (es)
JP (1) JP5680661B2 (es)
KR (1) KR101484590B1 (es)
CN (1) CN102665754B (es)
AR (1) AR079197A1 (es)
AU (1) AU2010324254B2 (es)
BR (1) BR112012012025B8 (es)
CA (1) CA2781173C (es)
CL (1) CL2012001030A1 (es)
CO (1) CO6501124A2 (es)
CU (1) CU23734A1 (es)
EA (1) EA021867B1 (es)
EC (1) ECSP12011803A (es)
ES (1) ES2643465T3 (es)
HK (1) HK1169961A1 (es)
MX (1) MX2012006077A (es)
MY (1) MY162324A (es)
NZ (1) NZ599792A (es)
PE (1) PE20121636A1 (es)
SG (1) SG181089A1 (es)
TN (1) TN2012000182A1 (es)
WO (1) WO2011063770A2 (es)
ZA (1) ZA201203762B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2655409A4 (en) 2010-12-22 2015-07-01 Univ Leland Stanford Junior SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
CA2925421C (en) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
AU2015233554B2 (en) 2014-03-17 2020-01-16 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Prasidenten A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
KR20190057113A (ko) 2016-09-28 2019-05-27 조마 (유에스) 엘엘씨 인터루킨-2에 결합하는 항체 및 그 용도
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
BR112019024127A2 (pt) 2017-05-24 2020-06-23 Pandion Therapeutics, Inc. Imunotolerância alvejada
CA3067909A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
KR20200086722A (ko) 2017-11-21 2020-07-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3773680A1 (en) * 2018-03-28 2021-02-17 Ascendis Pharma Oncology Division A/S Il-2 conjugates
CN112154153A (zh) 2018-03-28 2020-12-29 百时美施贵宝公司 白介素-2/白介素-2受体α融合蛋白以及使用方法
US20210253671A1 (en) * 2018-06-07 2021-08-19 Prottech Inc. Pharmaceutical Composition Containing Fusion Protein and Use Thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. ANTI-MADCAM IMMUNE TOLERANCE
KR102653906B1 (ko) 2020-01-14 2024-04-03 신테카인, 인크. 편향된 il2 뮤테인 방법 및 조성물
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CA3191260A1 (en) * 2020-09-04 2022-03-10 Yingying HU Il-2 mutant and application thereof
TW202233673A (zh) 2020-10-23 2022-09-01 美商雅雪生物治療公司 含調節免疫細胞功能之ｃｄ８抗原結合分子之融合物
US20240325495A1 (en) 2020-10-29 2024-10-03 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
WO2022229464A1 (en) 2021-04-30 2022-11-03 Tigen Pharma Sa Single vessel expansion of lymphocytes
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024097864A1 (en) 2022-11-02 2024-05-10 Tigen Pharma Sa Expansion of lymphocytes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
JP3024311B2 (ja) 1991-10-03 2000-03-21 味の素株式会社 Ｉｌ−２受容体重鎖に結合するポリペプチド
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
AU5300299A (en) 1998-08-21 2000-03-14 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides derived from il-2 and analogues thereof
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
EP2038417A2 (en) * 2006-07-06 2009-03-25 Merck Patent GmbH Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen

Also Published As

Publication number Publication date
AR079197A1 (es) 2012-01-04
ZA201203762B (en) 2013-01-30
WO2011063770A2 (es) 2011-06-03
WO2011063770A3 (es) 2011-09-09
KR101484590B1 (ko) 2015-01-22
CL2012001030A1 (es) 2012-07-20
EP2505206A2 (en) 2012-10-03
ECSP12011803A (es) 2012-07-31
EP2505206B1 (en) 2017-09-27
TN2012000182A1 (en) 2013-12-12
EA201290395A1 (ru) 2012-10-30
CU23734A1 (es) 2011-11-15
SG181089A1 (en) 2012-07-30
MX2012006077A (es) 2012-09-07
CA2781173C (en) 2015-10-13
AU2010324254A1 (en) 2012-05-31
AU2010324254B2 (en) 2014-01-09
BR112012012025B8 (pt) 2021-05-25
CN102665754A (zh) 2012-09-12
JP2013512200A (ja) 2013-04-11
CA2781173A1 (en) 2011-06-03
US8759486B2 (en) 2014-06-24
CN102665754B (zh) 2014-03-12
US20120315245A1 (en) 2012-12-13
EA021867B1 (ru) 2015-09-30
BR112012012025B1 (pt) 2021-05-11
NZ599792A (en) 2014-01-31
ES2643465T3 (es) 2017-11-23
CO6501124A2 (es) 2012-08-15
MY162324A (en) 2017-05-31
JP5680661B2 (ja) 2015-03-04
BR112012012025A2 (pt) 2016-05-17
KR20120106728A (ko) 2012-09-26
HK1169961A1 (en) 2013-02-15

Similar Documents

Publication Publication Date Title
PE20121636A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
EA201591766A1 (ru) Мутеины интерлейкина-2 для экспансии регуляторных т-клеток
CO6640254A2 (es) Método para preparar anticuerpos con propiedades mejoradas
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
CL2013001107A1 (es) Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas.
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
IN2015DN01115A (es)
TW201613958A (en) MIC-1 fusion proteins and uses thereof
CU24314B1 (es) Proteínas de fusión que comprenden factor de crecimiento de fibroblastos útil en desórdenes metabólicos
IN2013MN02442A (es)
PE20170957A1 (es) Agonistas parciales del receptor de insulina
CO6390070A2 (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i
PE20140303A1 (es) Polipeptidos interleuquina-2 mutantes
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
BRPI0508440A (pt) composições e métodos para diagnóstico tópico e transporte terapêutico
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
PE20130199A1 (es) Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores
SG10201903142RA (en) Serpin fusion polypeptides and methods of use thereof
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
BR112012015461A2 (pt) polipeptídeos de somatotropina boviina modificados e seus usos
MX2007003624A (es) Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas.
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
PH12016500708A1 (en) Recombinant glycoproteins and uses thereof
MX2018013177A (es) Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas.
TN2015000129A1 (en) POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF

Legal Events

Date Code Title Description
FC Refusal